High prevalence of tuberculosis is expected to drive the growth of India Rifampicin market.
According to TechSci Research report, “India Rifampicin Market By Source (In-house v/s Contract Manufacturing Organizations), By Form (Tablet, Capsule and Injection), By Route of Administration (Oral v/s Intravenous), By Distribution Channel (Online v/s Offline), By Application (Tuberculosis, Leprosy, Legionnaire’s Disease and Others), By End User (Adult v/s Paediatric), By Company, By Region, Forecast & Opportunities, FY2026”, the India rifampicin market is expected to grow at a steady rate during the forecast period for the treatment of tuberculosis. Rifampicin is an effective antibiotic against gram-positive bacteria such as mycobacteria. Therefore, it is being frequently used in the treatment of tuberculosis along with isoniazid, pyrazinamide and ethambutol/streptomycin. In addition to this, rifampicin is used alone in patients with latent tuberculosis infections to prevent or prolong the development of active disease which is expected to fuel the market growth through FY2026. However, side-effects associated with drug consumption such as temporary discoloration of your skin, teeth, saliva, urine, stool, sweat, and tears, itching, flushing, headache, drowsiness, dizziness, lack of coordination can restrict the market growth over the next few years. Moreover, increasing incidence of drug recall can further reduce the usage and application of the drug thereby hindering the market growth during the forecast period.
Browse XX market data Tables and XX Figures spread through XXX Pages and an in-depth TOC on “India Rifampicin Market”
The India rifampicin market is segmented based on source, form, route of administration, distribution channel, application, end user, company, and region. Based on route of administration, the market can be fragmented into oral v/s intravenous. The oral route of administration segment is expected to dominate the market in the forthcoming years on account of its versatility to accommodate various types of drugs. Moreover, the oral route is the most convenient and usually the safest, thereby positively influencing the segmental growth in the upcoming years. Based on source, the market can be categorized into in-house v/s contract manufacturing organizations. The in-house segment dominated the market until 2019 as most of the leading companies focus on in house production. Contract manufacturing organizations segment is expected to witness significant growth in the market as it saves cost and maximize profits. Besides, high growth in number of contract manufacturers is further contributing to its fast growing CAGR. In terms of form, the market is split into tablet, capsule, and injection. Among them, the capsule segment is anticipated to register high growth in the market over the next 5 years which is attributable to the fact that they are easy to use, readily available and tend to break down more quickly than tablets.
Indian Drugs and Pharmaceuticals Ltd., Cadila Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Lupin Laboratories Ltd., Concept Pharmaceuticals Ltd., Novartis India Ltd., Zydus Cadila Healthcare Ltd., Themis Pharmaceuticals Ltd., GlaxoSmithKline Pharmaceuticals Ltd, Taurus Laboratories Pvt. Ltd. and others are some of the leading players operating in India rifampicin market. Companies operating in the market are using Go-to-Market strategies such as product launches, mergers and acquisitions and research collaborations to boost their share and increase their geographic reach.
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7231
Customers can also request for 10% free customization on this report.
“India rifampicin market is expected to witness growth during the forecast period as it is used to treat patients with tuberculosis. It is estimated that about 40% of the Indian population is infected with TB bacteria. Additionally, major market players are focusing on strategic collaborations to commercialize their newly developed drugs. This is further expected to create lucrative opportunities for the market growth of India rifampicin market over the next five years.” said Mr. Karan Chechi, Research Director with TechSci Research, a research based India management consulting firm.
“India Rifampicin Market By Source (In-house v/s Contract Manufacturing Organizations), By Form (Tablet, Capsule and Injection), By Route of Administration (Oral v/s Intravenous), By Distribution Channel (Online v/s Offline), By Application (Tuberculosis, Leprosy, Legionnaire’s Disease and Others), By End User (Adult v/s Paediatric), By Company, By Region, Forecast & Opportunities, FY2026”, has evaluated the future growth potential of India rifampicin market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in India rifampicin market.
Mr. Ken Mathews
708 Third Avenue,
New York – 10017